度洛西汀和舍曲林治疗抑郁症的对照研究

A control study of duloxetine and sertraline in the treatment of patients with depression

目的:观察度洛西汀治疗抑郁症的疗效和安全性。方法:98例符合CCMD-3抑郁发作诊断标准的患者随机分为度洛西汀组(60mg/d,n=48)和舍曲林组(50～150mg/d,n=50),疗效采用汉密尔顿抑郁量表(HAMD)17项评分,不良反应采用治疗时出现的症状量表(TESS)和实验室检查来评定。疗程均为6周。结果:度洛西汀组痊愈率39.6%,有效率68.8%;舍曲林组痊愈率30.0%,有效率58.0%,两组比较差异无统计学意义。但度洛西汀组在HAMD量表减分值方面,第1、2、4周均更明显。度洛西汀最常见的不良反应为食欲减退或厌食、口干、出汗、便秘、恶心呕吐。两组脱落率分别为6.3%及8.0%,无统计学差异。结论:度洛西汀治疗抑郁症疗效好,不良反应少。

AIM： To study the efficacy and safety of duloxetine in the treatment of patients with depression. METHODS： In this 6-week randomized control trial, patients meeting CCMD-3 criteria for depressive episode were randomizedly divided to duloxetine group （60 mg/d, n = 48 ） and sertraline group （50 - 150 mg/d, n = 50）. Clinic effectiveness was evaluated using HAMD, adverse reactions and safety were assessed with TESS and laboratory examination. RESULTS： The remission rate and response rate were 39.6% and 68.8% for duloxetine group and 30.0% and 58.0% for sertraline group respectively, without statistically significant difference between two groups. But duloxetine-treated patients showed significantly greater improvement in the HAMD total score at week 1,2,4 respectively. The main adverse reactions were lack of appetite, dry mouth, sweating, constipation, nausea and vomit. The dropped out rates were 6.3 % for duloxetine group and 8.0% for sertraline group respectively, without statistically significant difference between two groups. CONCLUSION： Duloxetine appeared to be a safe and effective treatment for depression.